Supplier News: Kindeva, Evotec, RoslinCT & More
The latest from CDMOs, CMOs, and suppliers featuring Kindeva, Evotec, CurTec, Kaleo, RoslinCT, and CellFiber.
Biologics Manufacturing
* RoslinCT Receives Grant to Expand Digital Cell Therapy Operations
* CellFiber Launches New Subsidiary in US
Packaging
* Kindeva Awarded $226-M Contract from US Gov’t for Autoinjectors
* Kaléo Receives $96-M BARDA Contract for Autoinjectors
* CurTec Expands Warehouse and Packaging Capacity
Appointments
* Evotec Appoints New Chief Scientific Officer
Biologics Manufacturing
RoslinCT Receives Grant to Expand Digital Cell Therapy Operations
RoslinCT, a CDMO of cell therapies, has been awarded a research and development (R&D) grant from Scottish Enterprise, Scotland’s national economic development agency, to accelerate the digital transformation of its manufacturing operations in Scotland.
The funding, supported by a Scottish Enterprise R&D grant of up to £7.25 million ($9.6 million), forms part of RoslinCT’s digital expansion plan, a multi-year initiative designed to enhance the company’s integrated digital and AI capabilities.
Source: RoslinCT
CellFiber Launches New Subsidiary in US
CellFiber, a Tokyo-based biotechnology company developing 3D cell-culture and bioprocessing technology for regenerative medicine and cell-therapy manufacturing, has announced the opening of CellFiber, Inc., its first international subsidiary, which will focus on cell therapies, in Philadelphia, Pennsylvania. The subsidiary opened on October 1, 2026, with office and laboratory space in Philadelphia.
Source: CellFiber
Packaging
Kindeva Awarded $226-M Contract from US Gov’t for Autoinjectors
Kindeva’s global health security division, Meridian Medical Technologies, has been awarded a $226-million contract with the Defense Logistics Agency, part of the US Department of Defense, to provide antidote-treatment nerve-agent autoinjectors (ATNAA), with the potential of delivering over 3 million units from Kindeva’s autoinjector assembly center. Kindeva will manufacture the ATNAA auto injectors at its St. Louis, Missouri, campus.
Source: Kindeva
Kaléo Receives $96-M BARDA Contract for Autoinjectors
Kaléo, a provider of drug-delivery device and auto-injectors, has been awarded a $96.1-million contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS), to support the late-stage development, regulatory approval, and initial procurement of an auto-injector containing pralidoxime chloride for the treatment of organophosphate poisoning, including nerve agent exposure, in adult and certain pediatric populations. Additional options, if exercised by the US government, would expand the agreement, increasing the overall scope and value of the contract by an additional $244.8 million.
Source: Kaléo
CurTec Invests $10 M in Fine Chemicals and Packaging Mfg
CurTec, a packaging company, is investing $10 million to expand its Westminster, South Carolina, operations, to increase warehouse and production capacity for high-performance packaging used in fine chemicals and life-sciences products. A new blow–molding line will increase capacity and extend local production to smaller packaging sizes. The company plans to produce 6- and 10-liter click pack pails, plastic containers used for solid drug products, raw materials, and ingredients, in Westminster before year-end 2026, followed by smaller wide-neck drums in 2027.
The expansion will add approximately 27,300 square feet and more than 2,000 pallet positions. Groundbreaking is planned for October 2026, with completion expected in the second quarter of 2027.
Source: CurTec
Appointments
Evotec Appoints New Chief Scientific Officer
Evotec, a Hamburg, Germany-headquartered drug-discovery and development company and CDMO of biologics, has announced the appointment of Dr. Joanna Holbrook, currently Therapy Area Head, Cardiovascular, Renal and Hepatic Disease and Head of In Vitro Discovery Platforms at Novo, as Chief Scientific Officer and Member of the Management Board, effective November 1, 2026.
Dr. Holbrook has more than 25 years of experience as both a scientist and R&D leader. Prior to her role at Novo, she held positions at UK biotech companies Biomodal, where she served as Chief Scientific Officer, and BenevolentAI, where she was Vice President, Translational Medicine. She was also Professor of Bioinformatics at the University of Southampton in the UK and Senior Principal Investigator at the Singapore Institute for Clinical Sciences and adjunct Professor at National University of Singapore. She started her career at GSK, where she held positions of increasing responsibility across therapy areas and bioinformatics. She holds a Ph.D. in Molecular Cell Biology from University College London and a B.Sc. in Genetics from the University of Newcastle.
Source: Evotec
